CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

"... we will clear the pathway for execution of future R&D milestone events that we believe will be transformative for the Company and its shareholders."

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.